Insulin Sensitivity and β-Cell Function in Women With Polycystic Ovary Syndrome
Article Figures & Tables
Tables
- Table 1—
The indexes used for the evaluation of IR and βF derived from fasting, OGTT, and ITT measurements
Index Formula Reference βF HOMA-F (mIU/mmol) 20 × I0/(G0 − 3.5) 20 Insulinogenic index (I30 − I0)/(G30 − G0) 23 ΔI/ΔG30 (mIU/mmol) IR HOMA-R (mIU · mmol · 1−2) I0 × G0/22.5 20 FIRI (mIU · mmol · 1−2) I0 × G0/25 18 Suma I (mIU/1) I0 + I60 + I120 22 IS FGIR (mg/10−4 IU) G0/I0 21 Matsuda index (mmol−1 · mIU−1 · 12) 104/√[(mean I × mean G) × G0 × I0] 19 Cederholm index (mg · 12 · mmol−1 · mIU−1 · min−1) M/(mean G.log mean I) = [75,000/120 × (G0 − G120) × 1.15 × 180 × 0.19 × (m/120)]/[mean G × log mean I] 16 AUC-G/AUC-I AUC-G/AUC-I 17 KITT (min−1) 0,693/t1/2 14 DI βF × IS 40 - Table 2—
Comparison of anthropometry, OGTT, and ITT between PCOS and control subjects
Control PCOS (BMI <27) PCOS (BMI ≥27) Between-group differences Median Lower quartile Upper quartile Median Lower quartile Upper quartile Median Lower quartile Upper quartile P Significant between-group differences (P < 0.05) Age (years) 26.5 23.0 31.0 23.5 19.0 28.0 26.5 23.0 31.0 0.03 CL BMI (kg/m2) 21.4 20.5 23.7 21.8 20.3 24.2 31.0 28.7 33.8 0.0001 CO, LO WHR 77.79 75.27 83.18 87.00 82.00 93.10 100.00 95.60 103.10 0.0001 CL, CO, LO G0 (mmol/l) 4.40 4.30 4.75 4.70 4.60 4.70 4.70 4.70 4.70 0.004 CL, CO G30 (mmol/l) 7.20 6.75 7.75 6.55 5.50 7.40 8.00 6.80 8.90 0.0001 CO, LO G60 (mmol/l) 6.35 5.15 7.35 5.45 4.60 6.90 7.20 6.00 8.60 0.02 LO G120 (mmol/l) 4.85 4.15 5.40 4.80 4.00 5.40 5.05 4.10 5.90 NS — G180 (mmol/l) 3.65 3.45 4.30 4.10 3.80 4.90 4.10 3.90 4.60 0.01 CL, CO I0 (mIU/l) 6.78 5.64 10.50 8.80 5.70 12.50 16.80 6.00 25.70 0.005* CO, LO I30 (mIU/l) 49.75 32.19 64.86 52.65 35.00 74.50 133.50 57.60 162.10 0.00 CO, LO I60 (mIU/l) 52.65 45.22 79.14 43.65 26.00 94.60 117.50 64.50 192.20 0.0006* CO, LO I120 (mIU/l) 27.06 16.98 40.75 20.35 11.70 51.80 48.30 30.20 112.20 0.02* CO, LO I180 (mIU/l) 7.61 3.72 13.08 9.40 2.90 18.30 20.00 5.90 29.20 0.01 CO, LO Cp0 (nmol/l) 0.54 0.42 0.72 0.67 0.49 0.88 1.23 0.73 1.51 0.0001 CO, LO Cp30 (nmol/l) 2.45 1.92 2.78 2.69 1.76 3.22 3.53 2.38 4.43 0.0003 CO, LO Cp60 (nmol/l) 2.95 2.50 3.51 2.81 2.26 3.53 4.52 3.17 4.66 0.0001 CO, LO Cp120 (nmol/l) 2.45 2.09 2.62 2.03 1.24 2.76 3.36 2.16 4.04 0.003 CO, LO Cp180 (nmol/l) 0.89 0.75 1.47 1.05 0.66 1.44 1.58 1.17 2.37 0.003 CO, LO AUC-G 975.8 904.5 1,051.5 919.5 816 1,024 1,056 948 1,176 0.005 CO, LO AUC-I/1000 6.178 5.126 7.256 5.984 3.660 8.837 11.566 7.685 21.002 0.0007* CO, LO AUCCp 394.4 351.7 436.73 349.1 303 439.8 572.4 452.3 649.8 0.0001* CO, LO ΔI/ΔG30–0 15.41 10.04 18.326 22.99 12.92 44.82 34.807 15.55 56.696 0.0007 CL, CO HOMA-R 1.371 1.094 2.164 1.95 1.312 2.667 3.4658 1.292 5.7916 0.007 CO, LO HOMA-F 149.2 115.6 194.67 185 126.7 266.7 202.22 67.71 330.42 NS* — Matsuda 125.9 107.5 147.13 106 84 164.6 55.418 32.01 118 0.004 CO, LO FGIR 11.60 7.66 13.25 9.12 6.25 13.12 5.66 3.47 15.72 NS* — FIRI 1.23 0.98 1.95 1.75 1.18 2.40 3.09 1.20 5.14 0.05 CO, LO AUC-G/AUC-I 0.15 0.14 0.18 0.17 0.12 0.25 0.09 0.05 0.13 0.002* CO, LO Cederholm 63.00 54.32 77.37 71.47 55.15 86.52 51.75 40.64 62.76 0.003 CO, LO Suma I 98.28 73.40 116.30 73.00 50.90 133.5 161.20 121.2 307.90 0.0007* CO, LO KITT × 100 4.81 4.37 5.36 4.93 3.49 4.98 4.53 3.41 5.02 NS — ITTmin 2.00 1.70 2.40 2.40 2.10 3.80 2.50 2.20 2.80 0.004 CL, CO AUCITT 64.18 59.70 72.20 74.13 70.90 86.00 74.19 71.10 75.20 0.003 CL, CO - *
↵* Due to nonconstant variance even after transformation to minimum skewness of normalized residues with absolute values <2, Kruskal-Wallis test followed by Mann-Whitney U test was used instead of ANOVA. CL, control vs. lean PCOS subjects; CO, control vs. obese PCOS subjects; LO, lean vs. obese PCOS subjects.
- *
- Table 3—
Differences between PCOS and control subjects in DI
Insulin Control PCOS (BMI <27) PCOS (BMI ≥27) Between-group differences Secretion Sensitivity n Median Lower quartile Upper quartile n Median Lower quartile Upper quartile n Median Lower quartile Upper quartile P Significant between-group differences (P < 0.05) HOMA-F 1/HOMA-R 20 113.6 75.95 130.8 37 100 60 153.1 24 60 50.91 82.59 0.03 CO, LO HOMA-F I/I0 20 22.22 16.03 25 37 20 13.33 28.57 24 13.33 11.76 16.87 0.003 CO, LO HOMA-F G0/I0 20 97.78 76.09 107.5 37 94 66.67 122.3 24 66.67 57.02 79.3 0.002 CO, LO HOMA-F 1/FIRI 20 126.3 84.39 145.3 37 111.1 66.67 170.1 24 66.67 56.56 91.77 0.007 CO, LO ΔI/ΔG30-0 I/I120 20 0.649 0.357 0.965 36 1.104 0.475 2.555 24 0.679 0.28 1.252 0.007 CL, LO ΔI/ΔG30-0 AUC-G/AUC-I 20 0.112 0.045 0.169 35 0.182 0.056 0.558 23 0.066 0.016 0.134 0.0003 CO, LO, (CL) ΔI/ΔG30-0 Cederholm 20 906.3 581.8 1295 35 1634 882.4 2937 24 1554 962.8 2569 0.0003 CL, CO ΔI/ΔG30-0 Matsuda 20 1844 908.4 2294 36 2942 1398 4832 24 1946 1137 2787 0.05 CL, (LO) ΔI/ΔG30-0 1/Suma I 20 0.146 0.097 0.216 36 0.317 0.153 0.501 24 0.144 0.1 0.29 0.002 CL, LO HOMA-F KITT 20 7.276 5.533 10.15 5 11.59 9.582 13.5 8 8.828 2.469 20.85 NS* — HOMA-F 1/AUCITT 20 2.276 1.48 3.289 5 3.257 2.952 5.692 8 2.621 0.916 7.249 NS — HOMA-F 1/ITTmin 20 67.58 48.7 121.9 5 110 98.72 128.2 8 85.99 23.63 210.5 NS — ΔI/ΔG30-0 KITT 20 0.727 0.495 0.944 5 2.263 1.988 3.821 8 1.429 0.721 1.785 0.0001 CO, LO, CL ΔI/ΔG30-0 1/AUCITT 20 0.243 0.156 0.3 5 1.025 0.612 1.074 8 0.452 0.21 0.656 0.0008 LO, CL ΔI/ΔG30-0 1/ITTmin 20 6.648 4.564 11.2 5 21.5 20.48 29.72 8 14.57 6.295 16 0.0008 LO, CL - *
↵* Due to nonconstant variance even after transformation to minimum skewness of normalized residues with absolute values <2, Kruskall-Wallis test followed by Mann-Whitney U test was used instead of ANOVA. CL, control vs. lean PCOS subjects; CO, control vs. obese PCOS subjects; LO, lean vs. obese PCOS subjects.
- *
In this Issue
July 2002, 25(7)
Insulin Sensitivity and β-Cell Function in Women With Polycystic Ovary Syndrome
